Hepatitis C Virus. A European Perspective

Gastroenterology Clinics of North America

Volumn 44, Issue 4, 2015, Pages 807-824

  Dultz, Georg ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cirrhosis; Direct acting antiviral agents (DAA); European guidelines; Hepatitis C virus (HCV); Interferon free

Indexed keywords

BOCEPREVIR; DACLATASVIR; DASABUVIR; INTERFERON; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PLACEBO; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); CZECH REPUBLIC; DRUG APPROVAL; DRUG COST; EUROPE; FOOD AND DRUG ADMINISTRATION; FRANCE; GENOTYPE; GERMANY; HEALTH CARE SYSTEM; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MIGRANT; MORBIDITY; MORTALITY; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PUBLIC HEALTH PROBLEM; REVIEW; SCREENING TEST; SPAIN; SWEDEN; TREATMENT DURATION; VIRUS TRANSMISSION; COST OF ILLNESS; GENETICS; HEALTH CARE DELIVERY; HEPACIVIRUS; HEPATITIS C, CHRONIC; MULTIMODALITY CANCER THERAPY; TRANSMISSION; VIROLOGY;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; COST OF ILLNESS; EUROPE; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; PREVALENCE;

EID: 84947564170     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.07.008     Document Type: Review

References (82)

1. Perz J.F., Armstrong G.L., Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45(4):529-538.
2. Cornberg M., Razavi H.A., Alberti A., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011, 31(Suppl 2):30-60.
3. Gower E., Estes C., Blach S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61(1 Suppl):S45-S57.
4. Mohd Hanafiah K., Groeger J., Flaxman A.D., et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57(4):1333-1342.
5. Blachier M., Leleu H., Peck-Radosavljevic M., et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013, 58(3):593-608.
6. Bruggmann P., Berg T., Øvrehus A.L.H., et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014, 21(Suppl 1):5-33.
7. Gatselis N.K., Rigopoulou E., Stefos A., et al. Risk factors associated with HCV infection in semi-rural areas of central Greece. Eur J Intern Med 2007, 18(1):48-55.
8. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2):513-521. 521.e1-6.
9. Deuffic-Burban S., Deltenre P., Buti M., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012, 143(4):974-985.e14.
10. Razavi H., Waked I., Sarrazin C., et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014, 21(Suppl 1):34-59.
11. Krekulova L., Rehak V., Madrigal N., et al. Genotypic and epidemiologic characteristics of hepatitis C virus infections among recent injection drug user and nonuser populations. Clin Infect Dis 2001, 33(8):1435-1438.
12. Zabransky T., Mravcik V., Korcisova B., et al. Hepatitis C virus infection among injecting drug users in the Czech Republic - prevalence and associated factors. Eur Addict Res 2006, 12(3):151-160.
13. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014, 61(2):373-395.
14. European Association for Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60(2):392-420.
15. Rantala M., van de Laar M.J.W. Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 2008, 13(21). [pii:18880].
16. Saiz de la Hoya P., Marco A., García-Guerrero J., et al. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis 2011, 30(7):857-862.
17. Hüppe D., Zehnter E., Mauss S., et al. Epidemiologie der chronischen hepatitis C in Deutschland-Eine Analyse von 10,326 Hepatitis-C-Virus-Infizierten aus Schwerpunktpraxen und -ambulanzen. Z Gastroenterol 2008, 46(1):34-44.
18. Hahné S.J.M., Veldhuijzen I.K., Wiessing L., et al. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013, 13:181.
19. Delarocque-Astagneau E., Meffre C., Dubois F., et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010, 17(6):435-443.
20. Kautz A., Chavdarova L., Walker M. Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe. BMC Infect Dis 2014, 14(Suppl 6):S3.
21. European Centre for Disease Prevention and Control Surveillance and prevention of hepatitis B and C in Europe 2010, ECDC, Stockholm (Sweden).
22. Pomper G.J., Wu Y., Snyder E.L. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 2003, 10(6):412-418.
23. Mauser-Bunschoten E.P., Bresters D., van Drimmelen A.A., et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol 1995, 45(3):241-246.
24. Pipe S. Consideration in hemophilia therapy selection. Semin Hematol 2006, 43(2 Suppl 3):S23-S27.
25. Sauné K., Kamar N., Miédougé M., et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant 2011, 26(7):2309-2316.
26. Jadoul M., Poignet J., Geddes C., et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004, 19(4):904-909.
27. Martínez-Bauer E., Forns X., Armelles M., et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008, 48(1):20-27.
28. Deterding K., Wiegand J., Grüner N., et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009, 47(6):531-540.
29. Cozzolongo R., Osella A.R., Elba S., et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol 2009, 104(11):2740-2746.
30. Fusco M., Girardi E., Piselli P., et al. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer 2008, 44(6):847-853.
31. Lionis C., Koulentaki M., Biziagos E., et al. Current prevalence of hepatitis A, B and C in a well-defined area in rural Crete, Greece. J Viral Hepat 1997, 4(1):55-61.
32. Akcam F.Z., Uskun E., Avsar K., et al. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int J Infect Dis 2009, 13(2):274-284.
33. Turhan V., Ardic N., Eyigun C.P., et al. Investigation of the genotype distribution of hepatitis C virus among Turkish population in Turkey and various European countries. Chin Med J 2005, 118(16):1392-1394.
34. Mariano A., Scalia Tomba G., Tosti M.E., et al. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis 2009, 41(9):689-699.
35. Echevarría J.M., León P., Pozo F., et al. Follow-up of the prevalence of hepatitis C virus genotypes in Spain during a nine-year period (1996-2004). Enferm Infecc Microbiol Clin 2006, 24(1):20-25.
36. Ramos B., Núñez M., Toro C., et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 2007, 54(2):173-179.
37. Diamantis I., Bassetti S., Erb P., et al. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997, 26(4):794-797.
38. Garfein R.S., Vlahov D., Galai N., et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996, 86(5):655-661.
39. Hope V.D., Eramova I., Capurro D., et al. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014, 142(2):270-286.
40. Nelson P.K., Mathers B.M., Cowie B., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378(9791):571-583.
41. Demetriou V.L., van de Vijver D.A., Hezka J., et al. Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 2010, 82(2):263-270.
42. Reimer J., Lorenzen J., Baetz B., et al. Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007, 22(1):80-85.
43. Camoni L., Regine V., Salfa M.C., et al. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy. Ann Ist Super Sanita 2010, 46(1):59-65.
44. Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis 2014, 46(Suppl 5):S158-S164.
45. Wandeler G., Gsponer T., Bregenzer A., et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012, 55(10):1408-1416.
46. Hurley S.F., Jolley D.J., Kaldor J.M. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997, 349(9068):1797-1800.
47. Defossez G., Verneau A., Ingrand I., et al. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol 2008, 20(5):367-372.
48. Meffre C., Le Strat Y., Delarocque-Astagneau E., et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010, 82(4):546-555.
49. Jauffret-Roustide M., Le Strat Y., Couturier E., et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis 2009, 9:113.
50. Aceijas C., Hickman M., Donoghoe M.C., et al. Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction 2007, 102(8):1244-1250.
51. European Centre for Disease Prevention and Control Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies 2010, ECDC, Stockholm (Sweden).
52. Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48(1):148-162.
53. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl 1):S35-S50.
54. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345(1):41-52.
55. Mühlberger N., Schwarzer R., Lettmeier B., et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
56. World Health Organization. WHO Estimates for 2000-2012. Available at: . Accessed August 16, 2015. http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html.
57. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(9):558-567.
58. Adam R., Karam V., Delvart V., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012, 57(3):675-688.
59. Gane E.J., Stedman C.A., Hyland R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368(1):34-44.
60. Osinusi A., Meissner E.G., Lee Y., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013, 310(8):804-811.
61. Ruane P.J., Ain D., Stryker R., et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2014, 62(5):1040-1046.
62. Lawitz E., Sulkowski M.S., Ghalib R., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384(9956):1756-1765.
63. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370(3):211-221.
64. Zeuzem S., Jacobson I.M., Baykal T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370(17):1604-1614.
65. Feld J.J., Kowdley K.V., Coakley E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370(17):1594-1603.
66. Poordad F., Hezode C., Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370(21):1973-1982.
67. Ferenci P., Bernstein D., Lalezari J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014, 370(21):1983-1992.
68. Andreone P., Colombo M.G., Enejosa J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014, 147(2):359-365.e1.
69. Fried M.W., Forns X., Reau N., et al. TURQUOISE-II: regimens of ABT-450/r/ombitasvir and dasabuvir with ribavirin achieve high SVR12 rates in HCV genotype 1-infected patients with cirrhosis, regardless of baseline characteristics. Hepatology 2014, 60:238A.
70. Pol S., Reddy K.R., Baykal T., et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology 2014, 60:1129A.
71. Afdhal N., Reddy K.R., Nelson D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370(16):1483-1493.
72. Afdhal N., Zeuzem S., Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370(20):1889-1898.
73. Kowdley K.V., Gordon S.C., Reddy K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014, 370(20):1879-1888.
74. Reddy K.R., Bourlière M., Sulkowski M., et al. Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015, 62(1):79-86.
75. Kapoor R., Kohli A., Sidharthan S., et al. 240: All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology 2014, 60(Suppl 1):91A.
76. Jacobson I.M., Gordon S.C., Kowdley K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368(20):1867-1877.
77. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368(20):1878-1887.
78. Zeuzem S., Dusheiko G.M., Salupere R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014, 370(21):1993-2001.
79. Sarrazin C., Berg T., Buggisch P., et al. Aktuelle Empfehlung der DGVS und des bng zur Therapie der chronischen Hepatitis C. Z Gastroenterol 2014, 52(07):749-756.
80. Nelson D.R., Cooper J.N., Lalezari J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015, 61(4):1127-1135.
81. Gane E.J., Hyland R.H., An D., et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology 2014, 60:LB11.
82. Gane E.J., Hyland R.H., An D., et al. O6 sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014, 60(1):S3.